caa a22 4500 60617477X CHVBK 20210128100739.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s00018-015-1916-0 doi (NATIONALLICENCE)springer-10.1007/s00018-015-1916-0 Adaptation to antiangiogenic therapy in neurological tumors [Elektronische Daten] [Patrick Flanigan, Manish Aghi] Because tumors require a vascular supply for their survival and growth, angiogenesis is considered an important therapeutic target in most human cancers including cancer of the central nervous system. Antiangiogenic therapy has focused on inhibitors of the vascular endothelial growth factor (VEGF) signaling pathway. VEGF pathway-targeted drugs have shown therapeutic efficacy in several CNS tumors and have been tried most frequently in glioblastoma. These therapies, however, have been less effective than anticipated as some patients do not respond to therapy and some receive only modest benefit. Underlying this suboptimal response are multiple mechanisms of drug resistance involving changes in both tumor cells and their microenvironment. In this review, we discuss the multiple proposed mechanisms by which neurological tumors evolve to become resistant to antiangiogenic therapies. A better understanding of these mechanisms, their context, and their interplay will likely facilitate improvements in pharmacological strategies for the targeted treatment of neurological tumors. Springer Basel, 2015 Resistance nationallicence Adaptive nationallicence Glioblastoma nationallicence Bevacizumab nationallicence Pericytes nationallicence Bone marrow nationallicence Autophagy nationallicence Flanigan Patrick Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA aut Aghi Manish Department of Neurological Surgery, California Center for Pituitary Disorders, University of California, San Francisco, USA aut Cellular and Molecular Life Sciences Springer Basel 72/16(2015-08-01), 3069-3082 1420-682X 72:16<3069 2015 72 18 https://doi.org/10.1007/s00018-015-1916-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00018-015-1916-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Flanigan Patrick Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA aut NATIONALLICENCE 700 1- Aghi Manish Department of Neurological Surgery, California Center for Pituitary Disorders, University of California, San Francisco, USA aut NATIONALLICENCE 773 0- Cellular and Molecular Life Sciences Springer Basel 72/16(2015-08-01), 3069-3082 1420-682X 72:16<3069 2015 72 18